collapse Signs of sepsis: high fever or very low temperature, rapid breathing, confusion, or feeling extremely unwell following an injection Severe hypoglycaemia with loss of consciousness or inability to swallow Severe chest pain or significant difficulty breathing Contact your GP or a healthcare professional promptly if you experience: Injection site reactions such as persistent redness, swelling, warmth, or pain, which may indicate infection or an inflammatory response Systemic symptoms including fever, chills, or malaise following administration Gastrointestinal symptoms such as severe or persistent nausea, vomiting, or abdominal pain these are known effects associated with GLP-1 receptor agonism and may require clinical assessment [15] [6] Symptoms of hypoglycaemia shakiness, sweating, confusion, or palpitations particularly if retatrutide is being used alongside other glucose-lowering agents Cardiovascular symptoms such as a rapid or irregular heartbeat Report suspected side effects via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk

Clinicians should consider obtaining baseline lipid panels before initiating GLP-1 therapy, particularly in patients with known hypertriglyceridemia or other risk factors for pancreatitis
Note which side effects you experience and their severity
This eliminates the often-confusing maze of insurance and allows you to focus solely on your wellness goals
However, if patients are fully committed, they can achieve much more significant results. In a 2022 study, researchers monitored the weight loss of 175 patients who were overweight or obese and were taking semaglutide injections